BIO's Principles On Rx Value Lead With Research, But Emphasize Contracting
This article was originally published in The Pink Sheet Daily
As Congressional attention on pricing increases, BIO makes bid to reform the reimbursement landscape.
You may also be interested in...
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.